BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

```
     (FILE 'HOME' ENTERED AT 21:17:33 ON 23 FEB 2002)

     FILE 'REGISTRY' ENTERED AT 21:17:44 ON 23 FEB 2002
                E PSEUDOEPHEDRINE/CN
L1            9 S E3-E12

     FILE 'CAPLUS, USPATFULL' ENTERED AT 21:18:32 ON 23 FEB 2002
L2         1661 S L1
L3         2752 S (L2 OR PSEUDOEPHEDRIN#)
L4          101 S L3 AND MIGRAIN?
L5           56 S L4 AND PY <=1999
L6           56 DUP REM L5 (0 DUPLICATES REMOVED)
L7           17 S L3 (P) MIGRAIN?
L8           17 DUP REM L7 (0 DUPLICATES REMOVED)
```

```
=> s l3 (p) migrain?
L7          17 L3 (P) MIGRAIN?

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8           17 DUP REM L7 (0 DUPLICATES REMOVED)

=> d l8 abs ibib kwic 1-17

L8   ANSWER 1 OF 17  USPATFULL
AB     The invention provides a unit dose of an orally consumable material,
       having a predetermined pharmaceutically effective amount of at least one
       nonprescription discomfort reliever and a predetermined nutritionally
       effective amount of at least one nutritional supplement. Each unit dose
       may be in a container having indications of the amount discomfort
       reliever and the amount of nutritional supplement in each unit dose.
       Instructions are provided for consuming the material for discomfort
       relief and supplementing nutrition. Consumption of the unit dose
       simultaneously relieves discomfort and supplements nutrition.

ACCESSION NUMBER:        2002:37342  USPATFULL
TITLE:                   Unit dose of material in system and method
INVENTOR(S):             Lovercheck, Dale R., Media, PA, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2002022058      A1   20020221
APPLICATION INFO.:       US 2001-900647     A1   20010707  (9)

                              NUMBER        DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 2000-216924     20000708 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    Dale R. Lovercheck, Esquire, 92 Patricia Place, Media,
                         PA, 19063
NUMBER OF CLAIMS:        20
EXEMPLARY CLAIM:         1
LINE COUNT:              1019
DETD   . . . 250   Bayer Corp. under    Myers Squibb Co
         mg acetamino-      trademark: ONE A     under trademark
         phen, 250 mg       DAY ESSENTIAL        Excedrin Migraine
         aspirin and 65 mg                       (pain reliever tablets)
16       the nutritionally  nutritionally effect- 200 mg naproxin
         effective          ive components in    sold by. . . by Leiner
       hydramine HCl, 30 mg
         dephenhydramine    Health Products Inc. pseudoepherdrine HCl,
         HCl, 30 mg         under trademark      500 mg acetaminophen
           pseudoephedrine,   YOUR LIFE           sold by Park Davis
         HCl, and 500 mg    Immune System        under tradename
         acetaminophen      tablets              BENADRYL Allergy/
                                                 sinus/headache
22       500 mg vitamin     500 mg vitamin C     30 mg pseudoephed-
         C, 30 mg           sold by Leiner       rine HCl, 500 mg
           pseudoephedrine    Health Products Inc. acetaminophen sold
         HCl, and 500 mg    under trademark      by Warner Lambert
         acetaminophen      YOUR LIFE            under tradename
```

		Immune. . . caplets	
23	500 mg vitamin C, 30 mg **pseudoephedrine** HCl, 500 mg acetaminophen	500 mg vitamin C sold by Leiner Health Products Inc. under trademark YOUR LIFE Immune System. . .	30 mg pseudoephedrine HCl, 500 acetaminophen sold by Smith Kline Beecham under

DETD [0090] Trademarks of Bristol Myers Squibb Co. include Theragran Heart Right (multiple vitamin and mineral tablets), Excedrin **Migraine** (pain reliever tablets: containing 250 mg acetaminophen, 250 mg aspirin and 65 mg caffeine: as the active ingredients) and NO. . . . tablets (vitamin C 500 mg). Trademarks of Park Davis include BENADRYL Allergy/sinus/headache caplets containing 12.5 mg diphenhydramine HCl, 30 mg **pseudoephedrine** HCl, 500 acetaminophen). Trademarks of Warner Lambert include Sudafed Allergy caplets (30 mg **pseudoephedrine** HCl, 500 acetaminophen). Trademarks of Pfizer include Unison Sleep Tabs (25 mg oxyamine succinate). Trademarks of Smith Kline Beecham include CONTAC cold caplets (30 mg **pseudoephedrine** HCl, 500 acetaminophen). See also U.S. Pat. No. 5,895,663 incorporated herein by reference in its entirety.

L8 ANSWER 2 OF 17 USPATFULL

AB A medicinal composition for treating pain resulting from an inflammatory response comprises at least one pain relieving and anti-inflammatory pharmaceutical and at least one nutraceutical in a pharmaceutically acceptable base. The pharmaceutical is preferably acetaminophen or a non-steroidal anti-inflammatory drug (NSAID). The nutraceutical is preferably an immune booster, an anti-oxidant, a liver protectant, or a joint relief agent. Methods of using these compositions to treat pain caused by inflammation are also disclosed.

ACCESSION NUMBER:	2002:12069 USPATFULL
TITLE:	Composition and method for treating the effects of diseases and maladies
INVENTOR(S):	Gelber, Daniel, Woodland Hills, CA, UNITED STATES Kleinberger, Richard, Sherman Oaks, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002006445	A1	20020117	
APPLICATION INFO.:	US 2001-754204	A1	20010105	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184351	20000223 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Terry W. Kramer, Kramer & Associates, 2001 Jeff. Davis Hwy. Suite 1101, Arlington, VA, 22202
NUMBER OF CLAIMS:	126
EXEMPLARY CLAIM:	1
LINE COUNT:	1510

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis, which may include pharmaceutical ingredients, preferably selected from a group which includes, for example, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen,

ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis which includes formulating a composition which may include pharmaceutical ingredients preferably selected, for example, from. . . includes, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

L8 ANSWER 3 OF 17 USPATFULL

AB An improved medicinal composition includes an effective amount of a pain relieving and anti-inflammatory pharmaceutical and an effective amount of a nutraceutical in a pharmaceutically acceptable base. At least one of the pharmaceutical and the nutraceutical treats a condition caused by an immune response of the respiratory system, particularly an immune response that triggers the cough reflex. The pharmaceutical is preferably a cough suppressant, an expectorant, or a decongestant. The nutraceutical is preferably an immune booster, an antioxidant, a liver protectant, a nutraceutical which sedates the cough reflex, or a combination thereof. Methods of using these compositions to treat conditions caused by a respiratory immune response are also disclosed.

ACCESSION NUMBER:	2002:8081 USPATFULL		
TITLE:	Composition and method for treating the effects of diseases and maladies		
INVENTOR(S):	Gelber, Daniel, Woodland Hills, CA, UNITED STATES Kleinberger, Richard, Sherman Oaks, CA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004078	A1	20020110
APPLICATION INFO.:	US 2001-754205	A1	20010105 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-184351		20000223 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Terry W. Kramer, Kramer & Associates, 2001 Jeff. Davis Hwy. Suite 1101, Arlington, VA, 22202		
NUMBER OF CLAIMS:	130		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1510		

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis, which may include pharmaceutical ingredients, preferably selected from a group which includes, for example, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an

effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis which includes formulating a composition which may include pharmaceutical ingredients preferably selected, for example, from. . . includes, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

L8 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS

AB The present invention relates to a novel rapid-acting freeze-dried pharmaceutical compn. useful for the treatment of migraine and assocd. symptoms at a reduced total dose of active substance than required for oral administration in the form of a tablet. The compn. contains a porous matrix network of a water sol. or water dispersible carrier material, a pharmaceutically active substance(s), organoleptic additives such as sweetening agents, flavoring agents, and coloring agents, pharmaceutically acceptable preservatives, solubilizing agents, surface active agents and/or buffering agents. The pharmaceutical compn. optionally may contain other additives such as permeation enhancers, chelating salts and stabilizing agents. Advantages of the invention are: (1) rapid onset of action due to the rapid absorption of the active substance through oral mucosa, (2) reduced dosage of the drugs as absorption through oral mucosa bypasses the first-pass metab. and overcomes possible degrdn. in the gastrointestinal tract, (3) easy to administer to pediatric and geriatric patients, and (4) medicament can be taken without water. For example, tablets were prepd. by freeze drying to contain sumatriptan succinate 14.00 mg, ondansetron hydrochloride 5.0 mg, citric acid 1.68 mg, Na2HPO4 2.42 mg, polyvinyl chloride 3.0%, mannitol 25%, Me paraben sodium 0.1%, and Pr paraben sodium 0.01%.

ACCESSION NUMBER: 2001:416803 CAPLUS
DOCUMENT NUMBER: 135:24708
TITLE: A rapid acting freeze-dried oral pharmaceutical composition for treating migraine
INVENTOR(S): Venkateswara Rao, Pavuluri; Khadgapathi, Podili
PATENT ASSIGNEE(S): Natco Pharma Limited, India
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001039836	A1	20010607	WO 2000-IN78	20000825

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: IN 1999-MA1160 A 19991201
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 58-38-8, Prochlorperazine 58-73-1, Diphenhydramine **90-82-4**, **Pseudoephedrine** 103-90-2, Paracetamol 113-92-8, Chlorpheniramine maleate 364-62-5, Metoclopramide 523-87-5, Dimenhydrinate 9003-39-8, Polyvinylpyrrolidone 14838-15-4, Phenylpropanolamine 26159-34-2, Naproxen sodium 50679-08-8, Terfenadine 52468-60-7, Flunarizine 57808-66-9, Domperidone 83881-51-0, Cetirizine 99614-02-5, Ondansetron 109889-09-0, Granisetron
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapid-acting freeze-dried oral pharmaceuticals for **migraine** treatment)

L8 ANSWER 5 OF 17 USPATFULL
AB An improved medicinal composition includes an effective amount of an antihistamine pharmaceutical and an effective amount of a nutraceutical in a pharmaceutically acceptable base. At least one of the pharmaceutical and the nutraceutical treats a condition caused by an immune response to a virus, a microorganism, or an atmospheric pollutant or allergen. The medicinal composition may additionally include a pain relieving pharmaceutical or a decongestant. The nutraceutical is preferably an immune booster, an anti-oxidant, a liver protectant, or a combination thereof. Methods of using these compositions to treat conditions caused by an immune response are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:212415 USPATFULL
TITLE: Composition and method for treating the effects of diseases and maladies
INVENTOR(S): Gelber, Daniel, Woodland Hills, CA, United States
Kleinberger, Richard, Sherman Oaks, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001044411	A1	20011122
APPLICATION INFO.:	US 2001-754347	A1	20010105 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184351	20000223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Terry W. Kramer, Kramer & Associates, Suite 1101, 2001 Jeff. Davis Hwy., Arlington, VA, 22202
NUMBER OF CLAIMS: 106
EXEMPLARY CLAIM: 1
LINE COUNT: 1499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis, which may include pharmaceutical ingredients, preferably selected from a group which includes, for example, acetaminophen,

acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis which includes formulating a composition which may include pharmaceutical ingredients preferably selected, for example, from. . . includes, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

L8 ANSWER 6 OF 17 USPATFULL

AB An improved medicinal composition includes an effective amount of a pain relieving and anti-inflammatory pharmaceutical and an effective amount of a nutraceutical in a pharmaceutically acceptable base. At least one of the pharmaceutical and the nutraceutical treats a condition caused by an immune response to a virus, a microorganism, or an atmospheric pollutant or allergen. The pain relieving and anti-inflammatory pharmaceutical is preferably acetaminophen or a non-steroidal anti-inflammatory drug (NSAID). The medicinal composition may additionally include a pharmaceutical decongestant or antihistamine. The nutraceutical is preferably an immune booster, an anti-oxidant, a liver protectant, or a combination thereof. Methods of using these compositions to treat conditions caused by an immune response are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:212414 USPATFULL
TITLE:	Composition and method for treating the effects of diseases and maladies
INVENTOR(S):	Gelber, Daniel, Woodland Hills, CA, United States Kleinberger, Richard, Sherman Oaks, CA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001044410	A1	20011122	
APPLICATION INFO.:	US 2001-754125	A1	20010105	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184351	20000223 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Terry W. Kramer, Kramer & Associates, 2001 Jeff. Davis Hwy. Suite 1101, Arlington, VA, 22202
NUMBER OF CLAIMS:	110
EXEMPLARY CLAIM:	1
LINE COUNT:	1508

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and

arthritis, which may include pharmaceutical ingredients, preferably selected from a group which includes, for example, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis which includes formulating a composition which may include pharmaceutical ingredients preferably selected, for example, from. . . includes, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

L8 ANSWER 7 OF 17 USPATFULL

AB A medicinal composition for treating acid reflux disease comprises an effective amount of a pharmaceutical and an effective amount of a nutraceutical in a pharmaceutically acceptable base. The pharmaceutical is an acid-controlling pharmaceutical, such as cimetidine or ranitidine. The nutraceutical is a nutraceutical which is useful for treating stomach disorders, a nutraceutical which protects the mucosal linings of the digestive system, or a liver protectants. A method of using such a cmposition in the treatment of acid reflex disease is also disclosed.

ACCESSION NUMBER:	2001:211967 USPATFULL
TITLE:	Composition and method for treating the effects of diseases and maladies
INVENTOR(S):	Gelber, Daniel, Woodland Hills, CA, United States Kleinberger, Richard, Sherman Oaks, CA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001043959	A1	20011122	
APPLICATION INFO.:	US 2001-754348	A1	20010105	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184351	20000223 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Terry W. Kramer, Kramer & Associates, Suite 1101, 2001 Jeff. Davis Hwy., Arlington, VA, 22202
NUMBER OF CLAIMS:	134
EXEMPLARY CLAIM:	1
LINE COUNT:	1422

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis, which may include pharmaceutical ingredients, preferably selected from a group which includes, for example, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an

effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

SUMM . . . colds, flu, allergies, or sinus discomfort as well as treating pain and discomfort associated with heartburn, general body aches, headaches, **migraines**, menstruation, joint discomfort and arthritis which includes formulating a composition which may include pharmaceutical ingredients preferably selected, for example, from. . . includes, acetaminophen, acetylsalicylic acid or an effective salt thereof, ibuprofen, ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or an effective salt thereof, **pseudoephedrine** hydrochloride or an effective salt thereof, diphenhydramine hydrochloride or an effective salt thereof, clemastine fumarate or an effective salt thereof,. . .

L8 ANSWER 8 OF 17 USPATFULL

AB Disclosed is a system for delivery of a drug comprising a multiple unit dosing device comprising a housing and an actuator, said device containing multiple doses of multiparticulates comprising drug particles, said device upon actuation delivering a unit dose of said multiparticulates, said drug particles having a mean diameter of greater than 10 .mu.m to about 1 mm such that an effective dose of said drug cannot be delivered into the lower lung of a human patient. Also disclosed are novel methods, devices and dosage forms for delivering a drug.

ACCESSION NUMBER:	2001:150697 USPATFULL		
TITLE:	Delivery of oral drugs		
INVENTOR(S):	Staniforth, John, Bath, Great Britain Tobyn, Michael, Wileshire, Great Britain		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001020147	A1	20010906
APPLICATION INFO.:	US 2001-793304	A1	20010226 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	GB 2000-4701		20000228
	GB 2000-9023		20000412
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 Seventh Avenue, 14th Floor, New York, NY, 10018		
NUMBER OF CLAIMS:	91		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Page(s)		
LINE COUNT:	2247		

DETD . . . of hypertension such as propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril and hydralazine; drugs used in the treatment of **migraine** such as ergotamine; drugs affecting coagulability of blood such as epsilon aminocaproic acid and protamine sulfate; analgesic drugs such as. . . noscapine; mucolytic drugs such as carbocisteine; anti-septics such as cetylpyridinium chloride, tyrothricin and chlorhexidine; decongestant drugs such as phenylpropanolamine and **pseudoephedrine**; hypnotic drugs such as dichloralphenazone and nitrazepam; anti-nauseant drugs such as promethazine theoclate; haemopoietic drugs such as ferrous sulphate, folic. . . the present invention include, but are not

`limited to, H.sub.2 receptor antagonists, antibiotics, analgesics, cardiovascular agents, peptides or proteins, hormones, anti-**migraine** agents, anti-coagulant agents, anti-emetic agents, anti-hypertensive agents, narcotic antagonists, chelating agents, anti-anginal agents, chemotherapy agents, sedatives, anti-neoplastics, prostaglandins, antidiuretic agents. . . psylium, ciprofloxacin, theophylline, nifedipine, prednisone, prednisolone, ketoprofen, acetaminophen, ibuprofen, dexibuprofen lysinate, flurbiprofen, naproxen, codeine, morphine, sodium diclofenac, acetylsalicylic acid, caffeine, **pseudoephedrine**, phenylpropanolamine, diphenhydramine, chlorpheniramine, dextromethorphan, berberine, loperamide, mefenamic acid, flufenamic acid, astemizole, terfenadine, certirizine, phenytoin, guafenesin, N-acetylprocainamide HCl, pharmaceutically acceptable salts. . .

L8 ANSWER 9 OF 17 USPATFULL

AB Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) of a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100.degree. C., and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:105031 USPATFULL		
TITLE:	SOLID SOLUTION BEADLET		
INVENTOR(S):	BURNSIDE, BETH A., SILVER SPRING, MD, United States MCGUINNESS, CHARLOTTE M., BETHESDA, MD, United States RUDNIC, EDWARD M., NORTH POTOMAC, MD, United States COUCH, RICHARD A., BETHESDA, MD, United States GUO, XIAODI, DERWOOD, MD, United States TUSTIAN, ALEXANDER K., BOTHELL, WA, United States		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001006650	A1	20010705
APPLICATION INFO.:	US 1998-156464	A1	19980918 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1997-59408		19970919 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	RAYMOND J LILLIE, CARELLA BYRNE BAIN GILFILLAN CECCHI, STEWART & OLSTEIN, 6 BECKER FARM ROAD, ROSELAND, NJ, 07068		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	1157		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . antibiotics such as cephalosporin; antihistamines such as chlorpheniramine maleate, brompheniramine maleate, loratidine, astemizole, diclofenac sodium and terfenadine; decongestants such as **pseudoephedrine** and phenylephrine; antihypertensives such as ACE-inhibitors, verapamil, nifedipine, propanolol, metoprolol,

metoprolol succinate, metoprolol fumarate, metoprolol, methylphenadate, tartarate; agents to treat. . . and anti-epileptics such as valproate sodium, clonazepam, gabapetin, and topiramate; anti-depressives such as buspirone, fluoxeline, 5-hydroxytryptamine receptor agonist and antagonist; anti-**migraines** such as sumatreptan and dihydroergotamine; antipsychotics such as resperidone; antiemetics such as ondansetron; anti-heartburns such as cisapride; H2 receptor antagonists. . .

L8 ANSWER 10 OF 17 USPATFULL

AB A taste-masked micromatrix powder in which the ratio of a cationic copolymer synthesized form dimethylaminoethyl methacrylate and neutral methacrylic acid esters compared to a drug having poor organoleptic properties is greater than 2 to 1, preferably 4 to 1, most preferably 6 to 1 (wt/wt). Taste masked immediate release micromatrix powders can be formed by spray drying the drug and cationic copolymer whereas sustained release micromatrix powders can be formed by granulating controlled release powders, which can be made by spray drying the drug with a retarding polymer, with the cationic copolymer. The immediate release or sustained release taste-masked powders of this invention can be incorporated into conventional oral dosage forms such as sprinkles, suspension, fast melt tablets, chewable tablets or effervescent tablets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:160618 USPATFULL		
TITLE:	Taste-masked formulations		
INVENTOR(S):	Cumming, Kenneth Iain, Dublin, Ireland Harris, Elaine, Dublin, Ireland		
PATENT ASSIGNEE(S):	Elan Corporation, plc, Dublin, Ireland (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153220		20001128
APPLICATION INFO.:	US 1998-163731		19980930 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1997-60894		19971003 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spear, James M.		
LEGAL REPRESENTATIVE:	Anderson, Kirsten A.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	524		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . orally. Representative drugs include, but are not limited to, H.sub.2 receptor antagonists, antibiotics, analgesics, cardiovascular agents, peptides or proteins, hormones, anti-**migraine** agents, anti-coagulant agents, anti-emetic agents, anti-hypertensive agents, narcotic antagonists, chelating agents, anti-anginal agents, chemotherapy agents, sedatives, anti-neoplastics, prostaglandins, antidiuretic agents. . . psylium, ciprofloxacin, theophylline, nifedipine, prednisone, prednisolone, ketoprofen, acetaminophen, ibuprofen, dexibuprofen lysinate, flurbiprofen, naproxen, codeine, morphine, sodium diclofenac, acetylsalicylic acid, caffeine, **pseudoephedrine**, phenylpropanolamine, diphenhydramine,

chlorpheniramine, dextromethorphan, berberine, loperamide, mefenamic acid, flufenamic acid, astemizole, terfenadine, certirizine, phenytoin, guiafenesin, N-acetylprocainamide HCl, pharmaceutically acceptable salts. . .

L8 ANSWER 11 OF 17 USPATFULL

AB An orally administrable sustained-release dosage form includes particles of an active pharmaceutical ingredient which is coated with a polymeric material that is water-insoluble, but water-permeable and water-swellable, so that the sustained-release dosage form provides controlled release which is independent of certain variable physiological factors such as pH. In accordance with one aspect of the invention, the active pharmaceutical ingredient is acetaminophen and the coated acetaminophen particles are combined with uncoated acetaminophen particles to provide a combination immediate-release/sustained-release dosage form. In accordance with another aspect of the invention, the active pharmaceutical ingredient is coated with a methacrylate ester copolymer, and the coated particles are combined with uncoated particles of an active pharmaceutical ingredient to provide a combination immediate-release/sustained-release dosage form, wherein the sustained-release component provides a release rate which is substantially independent of physiological factors such as pH. The final orally administable dosage form can be appeared as compressed tablets, capsules or pouches.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:131443 USPATFULL
TITLE:	Immediate release/sustained release compressed tablets
INVENTOR(S):	Shah, Shirish A., Kalamazoo, MI, United States Ho, Chris Y., Kalamazoo, MI, United States
PATENT ASSIGNEE(S):	L. Perrigo Company, Allegan, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6126969		20001003
APPLICATION INFO.:	US 1997-962599		19971031 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-608839, filed on 27 Feb 1996, now patented, Pat. No. US 5736162		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Kulkosky, Peter F.
LEGAL REPRESENTATIVE:	Price, Heneveld, Cooper, DeWitt & Litton
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
LINE COUNT:	522

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . anti-infectives, psychotropics, anti-maniics, stimulants, anti-histamines, laxatives, decongestants, vitamins, gastro-intestinal sedatives, anti-diarrheal preparations, anti-anginal drugs, vasodilators, anti-arrhythmics, anti-hypertensive drugs, vasoconstrictors and **migraine** treatments, anti-coagulants and anti-thrombotic drugs, analgesics, anti-pyretics, hypnotics, sedatives, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypoglycemic agents, thyroid and. . . of hypertension such as propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril and hydralazine; drugs used in the treatment of **migraine** such as ergotamine; drugs affecting

coagulability of blood such as epsilon aminocaproic acid and protamine sulfate; analgesic drugs such as. . . noscapine; mucolytic drugs such as carbocisteine; anti-septics such as cetylpyridinium chloride, tyrothricin and chlorhexidine; decongestant drugs such as phenylpropanolamine and **pseudoephedrine**; hypnotic drugs such as dichloralphenazone and nitrazepam; anti-nauseant drugs such as promethazine theoclate; hemopoietic drugs such as ferrous sulphate, folic. . .

L8 ANSWER 12 OF 17 USPATFULL

AB A composition and procedures for its formation and administration are described, which provide for a convenient, efficacious and simple transdermal administration of medications from a topically applied cream. No transmission through a membrane is involved. The composition incorporates at least two separate penetration enhancers which function synergistically to provide for rapid but controllable transport of the medication from the cream into the skin. The use of a plurality of penetration enhancers, at least one of which facilitates the separation of medication from the cream and at least a second of which alters the structure of the outer layers of skin, particularly the stratum corneum, enhances migration of the drug through the stratum corneum.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:143696 USPATFULL
TITLE: Transdermal delivery of medications using a combination of penetration enhancers
INVENTOR(S): Grasela, John C., 4521 Saluto Ct., San Diego, CA, United States 92130
Grasela, Joseph E., 4767 Ocean Blvd., San Diego, CA, United States 92109
Jubenville, Robert M., 550 Washington St., San Diego, CA, United States 92103
McCloskey, Joseph J., 1167 Cooperwood, Bloomfield Hills, MI, United States 48302

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837289		19981117
APPLICATION INFO.:	US 1996-685172		19960723 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Shelborne, Kathryne E.
LEGAL REPRESENTATIVE: Brown, Martin, Haller & McClain, LLP
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 879
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . Disopyramide
Lidocaine
Tocainide
Mexiletine
Flecanide
Encainide
Amiodarone
Respiratory Drugs
Bronchodilators

Albuterol
Metaproterenol
Terbutaline
isoproterenol
Ephedrine
Theophylline
Dyphylline
Nasal Decongestants
Phenylpropanolamine
Pseudoephedrine
Phenylephrine
Ephedrine
Naphazoline
Oxymetazoline
Tetrahydrozoline
Xylometazoline
Propylhexedrine
Gastrointestinals
Sucralafate
Metoclopramide
Cisapride
Laxatives
Mesalamine
Olsalazine
Antidiarrheals
Famotidine
Nizatidine
Cimetadine
Rantadine
Omeprazol
. . . Diethylpropion
Mazindol
Fenfluramine
Dexfenfluramine
Antirheumatic Agents
Gold Compounds
Penicillamine
Azathioprine
Methotrexate
Agents for Gout
Probenecid
Sulfinpyrazone
Allopurinol
Colchicine
Agents for **Migraine**
Sumatriptan
Methysergide
Ergotamine Derivatives
Sedatives and Hypnotics
Zolpidem
Paraldehyde
Chloral Hydrate
Acetylcarbromal
Glutethimide
Ethchlorvynol
Ethimate
Temazepam
Estazolam

Flurazepam
Quazepam
Triazolam

. . .

L8 ANSWER 13 OF 17 USPATFULL

AB An orally administrable sustained-release dosage form includes particles of an active pharmaceutical ingredient which is coated with a polymeric material that is water-insoluble, but water-permeable and water-swellable, so that the sustained-release dosage form provides controlled release which is independent of certain variable physiological factors such as pH. In accordance with one aspect of the invention, the active pharmaceutical ingredient is acetaminophen and the coated acetaminophen particles are combined with uncoated acetaminophen particles to provide a combination immediate-release/sustained-release dosage form. In accordance with another aspect of the invention, the active pharmaceutical ingredient is coated with a methacrylate ester copolymer, and the coated particles are combined with uncoated particles of an active pharmaceutical ingredient to provide a combination immediate-release/sustained-release dosage form, wherein the sustained-release component provides a release rate which is substantially independent of physiological factors such as pH. The final orally administrable dosage form can be appeared as compressed tablets, capsules or pouches.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:75184 USPATFULL		
TITLE:	Acetaminophen sustained-release formulation		
INVENTOR(S):	Shah, Shirish A., Kalamazoo, MI, United States Ho, Chris Y., Kalamazoo, MI, United States		
PATENT ASSIGNEE(S):	L. Perrigo Company, Allegan, MI, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5773031		19980630
APPLICATION INFO.:	US 1996-608839		19960227 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kulkosky, Peter F.		
LEGAL REPRESENTATIVE:	Price, Heneveld, Cooper, Dewitt & Litton		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	533		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . anti-infectives, psychotropics, anti-maniics, stimulants, anti-histamines, laxatives, decongestants, vitamins, gastro-intestinal sedatives, anti-diarrheal preparations, anti-anginal drugs, vasodilators, anti-arrhythmics, anti-hypertensive drugs, vasoconstrictors and **migraine** treatments, anti-coagulants and anti-thrombotic drugs, analgesics, anti-pyretics, hypnotics, sedatives, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypoglycemic agents, thyroid and. . . of hypertension such as propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril and hydralazine; drugs used in the treatment of **migraine** such as ergotamine; drugs affecting coagulability of blood such, as epsilon aminocaproic acid and protaminc sulfate; analgesic drugs such as. . . noscapine; mucolytic drugs such

as carbocisteine; anti-septics such as cetylpyridinium chloride, tyrothricin and chlorhexidine; decongestant drugs such as phenylpropanolamine and **pseudoephedrine**; hypnotic drugs such as dichloralphenazone and nitrazepam; anti-nauseant drugs such as promethazine theoclate, hemopoietic drugs such as ferrous sulphate, folic. . .

L8 ANSWER 14 OF 17 USPATFULL

AB A controlled release powder containing discrete micro-particles for use in edible, pharmaceutical and other controlled release compositions is disclosed. The micro-particles have an average size in the range of from 0.1 to 125 .mu.m. Each of the micro-particles is in the form of a micromatrix of an active ingredient uniformly distributed in at least one non-toxic polymer. The micro-particles have a predetermined release of active ingredient when the dissolution rate thereof is measured according to the Paddle Method of U.S. Pharmacopoeia XX at 37.degree. C. and 75 r.p.m.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	94:88500 USPATFULL
TITLE:	Controlled release powder and process for its preparation
INVENTOR(S):	Sparks, Randall T., Gainesville, GA, United States Geoghegan, Edward J., Westmeath, Ireland
PATENT ASSIGNEE(S):	Elan Corporation, plc, Athlone, Ireland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5354556		19941011
APPLICATION INFO.:	US 1990-537065		19900709 (7)

DISCLAIMER DATE:	20070828
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-169447, filed on 17 Mar 1988, now patented, Pat. No. US 4952402 which is a continuation of Ser. No. US 1985-792801, filed on 30 Oct 1985, now patented, Pat. No. US 4940588

	NUMBER	DATE
PRIORITY INFORMATION:	IE 1984-278884	19841030

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Page, Thurman K.
ASSISTANT EXAMINER:	Harrison, R.
LEGAL REPRESENTATIVE:	Church, Marla J.
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT:	1139

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . of hypertension such as propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril and hydralazine; drugs used in the treatment of **migraine** such as ergotamine; drugs affecting coagulability of blood such as epsilon aminocaproic acid and protamine sulfate; analgesic drugs such as. . . noscapine; mucolytic drugs such as carbocisteine; anti-septics such as cetylpyridinium chloride, tyrothricin and chlorhexidine; decongestant drugs such as phenylpropanolamine and **pseudoephedrine**;

hypnotic drugs such as dichloralphenazone and nitrazepam; anti-nauseant drugs such as promethazine theoclate; haemopoietic drugs such as ferrous sulphate, folic. . .

L8 ANSWER 15 OF 17 USPATFULL

AB A controlled release powder containing discrete micro-particles for use in edible, pharmaceutical and other controlled release compositions is disclosed. The micro-particles have an average size in the range of from 0.1 to 125 .mu.m. Each of the micro-particles is in the form of a micromatrix of an active ingredient uniformly distributed in at least one non-toxic polymer. The micro-particles have a predetermined release of active ingedient when the dissolution rate thereof is measured according to the Paddle Method of U.S. Pharmacopoeia XX at 37.degree. C. and 75 r.p.m.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	90:67456 USPATFULL
TITLE:	Controlled release powder and process for its preparation
INVENTOR(S):	Sparks, Randall T., Gainesville, GA, United States Geoghegan, Edward J., Athlone, Ireland
PATENT ASSIGNEE(S):	Elan Corporation, p.l.c., Athlone, Ireland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4952402		19900828
APPLICATION INFO.:	US 1988-169447		19880317 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1985-792801, filed on 30 Oct 1985, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	IE 1984-2788	19841030

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Page, Thurman K.
LEGAL REPRESENTATIVE:	Falk, Robert Hardy, Croskell, Henry
NUMBER OF CLAIMS:	52
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT:	1310

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . of hypertension such as propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril and hydralazine; drugs used in the treatment of **migraine** such as ergotamine; drugs affecting coagulability of blood such as epsilon aminocaproic acid and protamine sulfate; analgesic drugs such as. . . noscapine; mucolytic drugs such as carbocisteine; anti-septics such as cetylpyridinium chloride, tyrothricin and chlorhexidine; decongestant drugs such as phenylpropanolamine and **pseudoephedrine**; hypnotic drugs such as dichloralphenazone and nitrazepam; anti-nauseant drugs such as promethazine theoclate; haemopoietic drugs such as ferrous sulphate, folic. . .

L8 ANSWER 16 OF 17 USPATFULL

AB A controlled release powder containing discrete micro-particles for use in edible, pharmaceutical and other controlled release compositions is

disclosed. The micro-particles have an average size in the range of from 0.1 to 125 .mu.m. Each of the micro-particles is in the form of a micromatrix of an active ingredient uniformly distributed in at least one non-toxic polymer. The micro-particles have a predetermined release of active ingredient when the dissolution rate thereof is measured according to the Paddle Method of U.S. Pharmacopoeia XX at 37.degree. C. and 75 r.p.m.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	90:54484 USPATFULL
TITLE:	Controlled release powder and process for its preparation
INVENTOR(S):	Sparks, Randall T., Gainesville, GA, United States Geoghegan, Edward J., Athlone, Ireland
PATENT ASSIGNEE(S):	Elan Corporation, Athlone, Ireland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4940588		19900710
APPLICATION INFO.:	US 1988-171131		19880317 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1985-792801, filed on 30 Oct 1985, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	IE 1984-2788	19841030

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Rose, Shep K.
LEGAL REPRESENTATIVE:	Falk, Robert H., Croskell, Henry
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT:	1123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . of hypertension such as propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril and hydralazine; drugs used in the treatment of **migraine** such as ergotamine; drugs affecting coagulability of blood such as epsilon aminocaproic acid and protamine sulfate; analgesic drugs such as. . . noscapine; mucolytic drugs such as carbocisteine; anti-septics such as cetylpyridinium chloride, tyrothricin and chlorhexidine; decongestant drugs such as phenylpropanolamine and **pseudoephedrine**; hypnotic drugs such as dichloralphenazone and nitrazepam; anti-nauseant drugs such as promethazine theoclate; haemopoietic drugs such as ferrous sulphate, folic. . .

L8 ANSWER 17 OF 17 USPATFULL

AB A carrier base material combined with a therapeutically active medicament and shaped and compressed to a solid unit dosage form having a regular and prolonged release pattern upon administration, the carrier base material being hydroxypropylmethylcellulose or a mixture of hydroxypropylmethylcellulose and up to 30% by weight of the mixture of ethylcellulose and/or up to 30% by weight of the mixture of sodium carboxymethylcellulose, and wherein the hydroxypropylmethylcellulose has a hydroxypropoxyl content of 9-12 weight % and a number average molecular weight of less than 50,000.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	83:2849 USPATFULL
TITLE:	Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
INVENTOR(S):	Schor, Joseph M., Locust Valley, NY, United States Nigalaye, Ashok, Elmhurst, NY, United States Gaylord, Norman G., New Providence, NJ, United States
PATENT ASSIGNEE(S):	Forest Laboratories Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4369172		19830118	
APPLICATION INFO.:	US 1981-332348		19811218	(6)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Rose, Shep K.
LEGAL REPRESENTATIVE:	Jacobs & Jacobs
NUMBER OF CLAIMS:	38
EXEMPLARY CLAIM:	1
LINE COUNT:	682

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . of hypertension such as propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril and hydralazine, drug used in the treatment of **migraine** such as ergotamine, drugs effecting coagulability of blood such as epsilon aminocaproic acid and protamine sulfate, analgesic drugs such as. . . noscapine, mucolytic drugs such as carbocisteine, anti-septics such as cetylpyridinium chloride, tyrothricin and chlorhexidine, decongestant drugs such as phenylpropanolamine and **pseudoephedrine**, hypnotic drugs such as dichloralphenazone and nitrazepam, anti-nauseant drug such as promethazine theoclate, haemopoetic drugs such as ferrous sulphate, folic. . .